ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15ColaLife
A 40 minute presentation covering the background to ColaLife, the ColaLife trial and progress towards scale-up. The presentation also covers the impacts and their measurement, the ColaLife Innovation Map and the scale-up version of the voucher system.
ColaLife Presentation to the Janssen Global Public Health Team, 26-Aug-15ColaLife
A 40 minute presentation covering the background to ColaLife, the ColaLife trial and progress towards scale-up. The presentation also covers the impacts and their measurement, the ColaLife Innovation Map and the scale-up version of the voucher system.
The role of innovation in augmenting healthcare - the ColaLife StoryColaLife
Presentation given by Simon Berry, CEO, ColaLife, at the Africa Health Extension Summit, 27-28 Nov 2019.
Key themes: why we need innovation in healthcare; what is innovation?; how to ensure innovations have an impact; how to move innovations into the mainstream.
Narrative is provided in the notes.
KYTS Programme Final Steering & Learning Group meeting 6-Sep-18ColaLife
Slidedeck to support the KYTS Programme Final Steering & Learning Group meeting on 6-Sep-18.
The KYTS Programme increased availability, access and use of ORS and Zinc therapy for home treatment of diarrhoea in children under 5 via private and public-sector development in Lusaka Province, Zambia
Considerations in Last Mile Delivery in Access to Medicines – the ColaLife StoryColaLife
Considerations in Last Mile Delivery in Access to Medicines
Out of the box thinking and partnership – the ColaLife Story.
This presentation was given at the 'Access to Medicines' conference hosted by Takeda in Geneva on 25-May-17. It describes how access to diarrhoea treatment was transformed in Zambia.
Diarrhoea is the second biggest infectious killer of under 5 children and yet we know how to treat diarrhoea and the medicine is simple, safe and cheap. The problem is that 99% of diarrhoea cases do not receive the recommended treatment: ORS and Zinc. The last remaining barrier is access.
ColaLife - Cross-sector partnerships - new paradigmsColaLife
Presentation to the Stakeholder Engagement Event at Middlesex University outlining how ColaLife had partnered with the academic sector in our work. 6-Jul-16.
Progress update on the Kit Yamoyo scale-up in Zambia for the stakeholders who support public health in Zambia. The meeting was held at the CDC offices in Lusaka.
For on-going updates please see: http://colalife.org/status
Royal Society of Medicine - Medical Innovations - Kit Yamoyo and its value chainColaLife
Presentation given by ColaLife's Simon Berry at the Royal Society of Medicine's 11th Medical Innovations Summit 2015 on 12-Sep-15.
This includes a brief history of ColaLife, the learning from the operational trial in Zambia and progress towards national scale-up.
ColaLife presentation to the ANDi Workshop, Addis Ababa, Jan-15ColaLife
ColaLife presentation to the ANDi Workshop, Addis Ababa, Jan-15. The presentation is just 5 minutes long and has six sections:
1. The scope of our work
2. Our starting point
3. What we did
4. What happened
5. The effects
6. recommendations for ANDi
Kit Yamoyo design review - how the trial findings influenced the design of the Kit Yamoyo anti-diarrhoea kit used in the subsequent national scale-up in Zambia.
Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14ColaLife
Presentation to PATH staff on 23-May-14.
Delivered in Seattle with a video link to Washington and audio link to San Francisco.
Download the presentation for the speech narrative that is contained in the notes to the slides.
Presentation to University of Michigan | 19-May-14ColaLife
Presentation to the University of Michigan, 19-May-14, Ann Arbor, Michigan at the invitation of the William Davidson Institute.
Download the presentation for the speech narrative that is contained in the notes to the slides.
After dinner speech at the 26th DuPont Packaging Awards, 15-May-14, Wilmington, Delaware, USA.
Download the presentation for the speech narrative that is contained in the notes to the slides.
ColaLife presention to C2MTL | 28-May-2014ColaLife
Keynote presentation given at C2MTL on 28-May-2014.
20 mins, fully annotated.
This gives the brief history of ColaLife, describes the ColaLife Trial in Zambia (COTZ), presents our key findings and describes our strategy for impact.
ColaLife | Key milestones - 1985 to Dec-13ColaLife
This timeline highlights some of the key milestones since the birth of the ColaLife idea in 1985 to the end of the trial and move to scale-up in Dec-13.
It focussed on the key people involved and describes how the relationship with The Coca-Cola Company and SABMiller has developed.
Additional milestone:
May 2010
Together, Simon, Jane and Rohit submitted their first proposal to the Clinton Health Access Initiative (CHAI) who were seeking out innovative financing and delivery mechanisms for ACTs under the Affordable Medicines Facility for Malaria (AMFm).
The proposal got to final stages of consideration and reinforced the global interest in and potential of the model.
Correction: Rohit Ramchandani's title at CIDA was Senior Health Advisor, not Public Policy Advisor.
Presentation at the Institution of Mechanical Engineers - Appropriate Healthcare Technologies for Developing Countries - 18 September 2013
This presentation includes the narrative in the notes. Please download it to see these.
Presentation to the International Society for Neglected Tropical Diseases - 1...ColaLife
A description of ColaLife's Operational Trial in Zambia including sales data for the Kit Yamoyo to 25 Jan 2013 and an analysis of the role of private sector partners during the different phases of the project.
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
The role of innovation in augmenting healthcare - the ColaLife StoryColaLife
Presentation given by Simon Berry, CEO, ColaLife, at the Africa Health Extension Summit, 27-28 Nov 2019.
Key themes: why we need innovation in healthcare; what is innovation?; how to ensure innovations have an impact; how to move innovations into the mainstream.
Narrative is provided in the notes.
KYTS Programme Final Steering & Learning Group meeting 6-Sep-18ColaLife
Slidedeck to support the KYTS Programme Final Steering & Learning Group meeting on 6-Sep-18.
The KYTS Programme increased availability, access and use of ORS and Zinc therapy for home treatment of diarrhoea in children under 5 via private and public-sector development in Lusaka Province, Zambia
Considerations in Last Mile Delivery in Access to Medicines – the ColaLife StoryColaLife
Considerations in Last Mile Delivery in Access to Medicines
Out of the box thinking and partnership – the ColaLife Story.
This presentation was given at the 'Access to Medicines' conference hosted by Takeda in Geneva on 25-May-17. It describes how access to diarrhoea treatment was transformed in Zambia.
Diarrhoea is the second biggest infectious killer of under 5 children and yet we know how to treat diarrhoea and the medicine is simple, safe and cheap. The problem is that 99% of diarrhoea cases do not receive the recommended treatment: ORS and Zinc. The last remaining barrier is access.
ColaLife - Cross-sector partnerships - new paradigmsColaLife
Presentation to the Stakeholder Engagement Event at Middlesex University outlining how ColaLife had partnered with the academic sector in our work. 6-Jul-16.
Progress update on the Kit Yamoyo scale-up in Zambia for the stakeholders who support public health in Zambia. The meeting was held at the CDC offices in Lusaka.
For on-going updates please see: http://colalife.org/status
Royal Society of Medicine - Medical Innovations - Kit Yamoyo and its value chainColaLife
Presentation given by ColaLife's Simon Berry at the Royal Society of Medicine's 11th Medical Innovations Summit 2015 on 12-Sep-15.
This includes a brief history of ColaLife, the learning from the operational trial in Zambia and progress towards national scale-up.
ColaLife presentation to the ANDi Workshop, Addis Ababa, Jan-15ColaLife
ColaLife presentation to the ANDi Workshop, Addis Ababa, Jan-15. The presentation is just 5 minutes long and has six sections:
1. The scope of our work
2. Our starting point
3. What we did
4. What happened
5. The effects
6. recommendations for ANDi
Kit Yamoyo design review - how the trial findings influenced the design of the Kit Yamoyo anti-diarrhoea kit used in the subsequent national scale-up in Zambia.
Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14ColaLife
Presentation to PATH staff on 23-May-14.
Delivered in Seattle with a video link to Washington and audio link to San Francisco.
Download the presentation for the speech narrative that is contained in the notes to the slides.
Presentation to University of Michigan | 19-May-14ColaLife
Presentation to the University of Michigan, 19-May-14, Ann Arbor, Michigan at the invitation of the William Davidson Institute.
Download the presentation for the speech narrative that is contained in the notes to the slides.
After dinner speech at the 26th DuPont Packaging Awards, 15-May-14, Wilmington, Delaware, USA.
Download the presentation for the speech narrative that is contained in the notes to the slides.
ColaLife presention to C2MTL | 28-May-2014ColaLife
Keynote presentation given at C2MTL on 28-May-2014.
20 mins, fully annotated.
This gives the brief history of ColaLife, describes the ColaLife Trial in Zambia (COTZ), presents our key findings and describes our strategy for impact.
ColaLife | Key milestones - 1985 to Dec-13ColaLife
This timeline highlights some of the key milestones since the birth of the ColaLife idea in 1985 to the end of the trial and move to scale-up in Dec-13.
It focussed on the key people involved and describes how the relationship with The Coca-Cola Company and SABMiller has developed.
Additional milestone:
May 2010
Together, Simon, Jane and Rohit submitted their first proposal to the Clinton Health Access Initiative (CHAI) who were seeking out innovative financing and delivery mechanisms for ACTs under the Affordable Medicines Facility for Malaria (AMFm).
The proposal got to final stages of consideration and reinforced the global interest in and potential of the model.
Correction: Rohit Ramchandani's title at CIDA was Senior Health Advisor, not Public Policy Advisor.
Presentation at the Institution of Mechanical Engineers - Appropriate Healthcare Technologies for Developing Countries - 18 September 2013
This presentation includes the narrative in the notes. Please download it to see these.
Presentation to the International Society for Neglected Tropical Diseases - 1...ColaLife
A description of ColaLife's Operational Trial in Zambia including sales data for the Kit Yamoyo to 25 Jan 2013 and an analysis of the role of private sector partners during the different phases of the project.
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
3. Headline findings
from the Kit Yamoyo trial
Sep-12 to Aug-13
14The perception of
ORS as an
effective
treatment for
diarrhoea
increased by 14
percentage
points.
>26k
kits sold into the
two remote rural
trial areas in
12 months.
45%of children in trial
areas received
ORS/Zinc. Up
from a baseline
of <1%.
Comparator sites
stayed at <1%.
(OR 20.4, p<0.001)
2.4km
The distance to
ORS/Zinc in the
trial areas was
reduced by two-
thirds from
7.3km to 2.4km.
(p<0.001)
93%of Kit Yamoyo
users mixed ORS
correctly. Only
60% do when
given 1 litre
sachets.
(OR 1.84, p<0.05)
6. Tonight’s beer and soft drinks have been provided
courtesy of Zambian Breweries part of the SABMiller
Group.
SABMiller were partners in the Kit Yamoyo trial providing:
• Advice of value chain creation
• Funding and meeting facilities
20. Progress towards national scale-up
Control districts
Trial – Sep-12 to Sep-13
Intervention districts
21. Progress towards national scale-up
Control districts
Trial – Sep-12 to Sep-13
Transition – from Oct-13
Transition districts
Intervention districts
22. Progress towards national scale-up
Control districts
Trial – Sep-12 to Sep-13
Transition – from Oct-13
Transition districts
Intervention districts
Activity in Southern Province stopped in
Nov-14 due to a lack of funding. We plan
to re-start marketing in early 2016.
23. Progress towards national scale-up
Scale-up
Control districts
Trial – Sep-12 to Sep-13
Transition – from Oct-13
Transition districts
Intervention districts
KYTS-ACE – from Feb-15
Activity in Southern Province stopped in
Nov-14 due to a lack of funding. We plan
to re-start marketing in early 2016.
24. Progress towards national scale-up
Activity in Southern Province stopped in
Nov-14 due to a lack of funding. We plan
to re-start marketing in early 2016.
Scale-up
Control districts
KYTS-LUSAKA – from Oct-15
Trial – Sep-12 to Sep-13
Transition – from Oct-13
Transition districts
Intervention districts
KYTS-ACE – from Feb-15
25. Scale-up
Control districts
KYTS-LUSAKA – from Oct-15
Trial – Sep-12 to Sep-13
Transition – from Oct-13
Transition districts
Intervention districts
KYTS-ACE – from Feb-15
Progress towards national scale-up
KYTS-SHOPRITE – from Dec-15
Activity in Southern Province stopped in
Nov-14 due to a lack of funding. We plan
to re-start marketing in early 2016.
26. Tonight’s beer and soft drinks have been provided
courtesy of Zambian Breweries part of the SABMiller
Group.
SABMiller were partners in the Kit Yamoyo trial providing:
• Advice of value chain creation
• Funding and meeting facilities
27. Thank you to the Kit Yamoyo funders
Isenberg Family
Charitable Foundation
Editor's Notes
This presentation describes the progress of UK charity ColaLife from its initial concept to ‘piggyback’ simple medicines, at the ‘last mile’ of distribution in developing countries, through to the results and learning from the 2-year trial in Zambia, to scale-up plans to cover the whole of Zambia and spread designs and learning more widely.
However, another surprising result: shop-keepers did not find it helpful to be able to pack Kit Yamoyo into Cola crates at the point of purchase…
Anyone can have access to these findings, by registering their interest with us.
Thanks to DfID funding we will start scale-up where most people live - over 2 million of Zambia’s 13 million people live here.
As the final step to national scale-up we will seek support to develop the market in the Copperbelt (green circle) where another 2 milllion live.
Thanks to DfID funding we will start scale-up where most people live - over 2 million of Zambia’s 13 million people live here.
As the final step to national scale-up we will seek support to develop the market in the Copperbelt (green circle) where another 2 milllion live.
Thanks to DfID funding we will start scale-up where most people live - over 2 million of Zambia’s 13 million people live here.
As the final step to national scale-up we will seek support to develop the market in the Copperbelt (green circle) where another 2 milllion live.
Thanks to DfID funding we will start scale-up where most people live - over 2 million of Zambia’s 13 million people live here.
As the final step to national scale-up we will seek support to develop the market in the Copperbelt (green circle) where another 2 milllion live.
Thanks to DfID funding we will start scale-up where most people live - over 2 million of Zambia’s 13 million people live here.
As the final step to national scale-up we will seek support to develop the market in the Copperbelt (green circle) where another 2 milllion live.
Thanks to DfID funding we will start scale-up where most people live - over 2 million of Zambia’s 13 million people live here.
As the final step to national scale-up we will seek support to develop the market in the Copperbelt (green circle) where another 2 milllion live.
Thanks to DfID funding we will start scale-up where most people live - over 2 million of Zambia’s 13 million people live here.
As the final step to national scale-up we will seek support to develop the market in the Copperbelt (green circle) where another 2 milllion live.
It was the early commitment of funds to the ColaLife idea that leveraged all the other support for the trial and subsequent to the trial additional funders have come on-board. Notably Ceniarth and the Isenberg Family Charitable Foundation have provided ‘catalytic’ funding and we have always enjoyed support from individual supporters.